Review article: Thrombocytopenia in chronic liver disease

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 5-11

  Poordad, F ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; AMG 531; ANTITHROMBOCYTIC AGENT; ELTROMBOPAG; INTERLEUKIN 11; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; UNCLASSIFIED DRUG;

ALLOIMMUNIZATION; ARTIFICIAL EMBOLISM; BACTERIAL INFECTION; BLEEDING; CHRONIC LIVER DISEASE; CLINICAL DECISION MAKING; CLINICAL INDICATOR; CLINICAL PROTOCOL; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; FEVER; HEALTH CARE COST; HUMAN; LIVER BIOPSY; OUTCOMES RESEARCH; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REFRACTORY THROMBOCYTOPENIA; REVIEW; SPLEEN ARTERY; THROMBOCYTE; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VIRUS INFECTION;

BLOOD COAGULATION DISORDERS; CHRONIC DISEASE; HUMANS; LIVER DISEASES; PATIENT CARE MANAGEMENT; PLATELET COUNT; PLATELET TRANSFUSION; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 35448948184     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03510.x     Document Type: Review

References (59)

1. Wallace MJ, Churchill WH, Surgenor DM, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 1995 35 : 802 12.
2. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000 95 : 2936 9.
3. Giannini EG. Review article: Thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2003 23 : 1055 65.
4. Bordin G, Ballare M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995 13 (Suppl. 13 S39 43.
5. Wang CS, Yao WJ, Wang ST, Chang TT, Chou P. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. Clin Infect Dis 2004 39 : 790 6.
6. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004 71 (Suppl. 3 S17 21.
7. Oh S, Afdhal NH. Antiviral therapy for treatment naïve patients with hepatitis C virus. Infect Dis Clin N Am 2006 20 : 99 113.
8. Williford SK, Salisbury PL III., Peacock JE Jr., et al. The safety of dental extractions in patients with hematologic malignancies. J Clin Oncol 1989 7 : 798 802.
9. Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004 6 : 30 6.
10. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 64.
11. Murphy MF, Waters AH. Clinical aspects of platelet transfusions. Blood Coagul Fibrinolysis 1991 2 : 389 96.
12. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000 37 (Suppl. 4 3 10.
13. Jalan R, Redhead DN, Allan PL, Hayes PC. Prospective evaluation of haematological alterations following the transjugular intrahepatic portosystemic stent-shunt (TIPSS). Eur J Gastroenterol Hepatol 1996 8 : 381 5.
14. Ong JP, Sands M, Younossi ZM. Transjugular intrahepatic portosystemic shunts (TIPS): a decade later. J Clin Gastroenterol 2000 30 : 14 28.
15. Giannini EG, Botta F, Borro P, et al. Application of the platelet count/spleen diameter ratio to rule out the presence of oesophageal varices in patients with cirrhosis: a validation study based on follow-up. Dig Liver Dis 2005 37 : 779 85.
16. Czaja AJ, Wolf AM, Baggenstoss AH. Clinical assessment of cirrhosis in severe chronic active liver disease: specificity and sensitivity of physical and laboratory findings. Mayo Clin Proc 1980 55 : 360 4.
17. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.
18. PEGASYS® (peginterferon alfa-2a) Prescribing Information. Nutley, NJ : Roche Pharmaceuticals, 2004.
19. Homoncik M, Ferlitsch A, Ferenci P, et al. Short- and long-term effects of therapy with interferon-alpha and pegylated interferon-alpha/ribavirin on platelet plug formation and von Willebrand factor release in patients with chronic hepatitis C. Aliment Pharmacol Ther 2005 21 : 49 55.
20. Segal JB, Dzik WH. Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005 45 : 1413 25.
21. Cobb WS, Heniford BT, Burns JM, Carbonell AM, Matthews BD, Kercher KW. Cirrhosis is not a contraindication to laparoscopic surgery. Surg Endosc 2005 19 : 418 23.
22. Lin CH, Shih FY, Ma MH, Chiang WC, Yang CW, Ko PC. Should bleeding tendency deter abdominal paracentesis? Dig Liver Dis 2005 37 : 946 51.
23. Grabau CM, Crago SF, Hoff LK, et al. Performance standards for therapeutic abdominal paracentesis. Hepatology 2004 40 : 484 8.
24. McVay PA, Toy PT. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion 1991 31 : 164 71.
25. Senzolo M, Burra P, Cholongitas E, Burroughs AK. New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol 2006 12 : 7725 36.
26. Inabnet WB, Deziel DJ. Laparoscopic liver biopsy in patients with coagulopathy, portal hypertension, and ascites. Am Surg 1995 61 : 603 6.
27. Smith TP, Presson TL, Heneghan MA, Ryan JM. Transjugular biopsy of the liver in pediatric and adult patients using an 18-gauge automated core biopsy needle: a retrospective review of 410 consecutive procedures. Am J Roentgenol 2003 180 : 167 72.
28. Sharma P, McDonald GB, Banaji M. The risk of bleeding after percutaneous liver biopsy: relation to platelet count. J Clin Gastroenterol 1982 4 : 451 3.
29. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol 1990 94 : 747 53.
30. Ito K, Shiraki K, Sakai T, Yoshimura H, Nakano T. Portal hypertensive colopathy in patients with liver cirrhosis. World J Gastroenterol 2005 11 : 3127 30.
31. Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Des 2002 8 : 369 77.
32. Rinder HM, Arbini AA, Snyder EL. Optimal dosing and triggers for prophylactic use of platelet transfusions. Curr Opin Hematol 1999 6 : 437 41.
33. Rebulla P. Trigger for platelet transfusion. Vox Sang 2000 78 (Suppl. 2 179 82.
34. Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001 19 : 1519 38.
35. Rebulla P. Platelet transfusion trigger in difficult patients. Transfus Clin Biol 2001 8 : 249 54.
36. Kaushansky K. Thrombopoietin. N Engl J Med 1998 339 : 746 54.
37. Shah R, Mahour GH, Ford EG, Stanley P. Partial splenic embolization. An effective alternative to splenectomy for hypersplenism. Am Surg 1990 56 : 774 7.
38. Sangro B, Bilbao I, Herrero I, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993 18 : 309 414.
39. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000 14 : 1009 31.
40. Romano M, Giojelli A, Capuano G, Pomponi D, Salvatore M. Partial splenic embolization in patients with idiopathic portal hypertension. Eur J Radiol 2004 49 : 268 73.
41. Palsson B, Verbaan H. Partial splenic embolization as pretreatment for antiviral therapy in hepatitis C virus infection. Eur J Gastroenterol Hepatol 2005 17 : 1153 5.
42. Kato M, Shimohashi N, Ouchi J, Yoshida K, Tanabe Y, Takenaka K. Partial splenic embolization facilitates completion of interferon therapy in patients with chronic HCV infection and hypersplenism. J Gastroenterol 2005 40 : 1076 7.
43. Ochs A. Transjugular intrahepatic portosystemic shunt. Dig Dis 2005 23 : 56 64.
44. Wong F. The use of TIPS in chronic liver disease. Ann Hepatol 2006 5 : 5 15.
45. Karasu Z, Gurakar A, Kerwin B, et al. Effect of transjugular intrahepatic portosystemic shunt on thrombocytopenia associated with cirrhosis. Dig Dis Sci 2000 45 : 1971 6.
46. Gabrilove J. Overview: erythropoiesis, anemia, and the impact of erythropoietin. Semin Hematol 2000 37 (Suppl. 6 1 3.
47. Desai J, Demetri GD. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review. Best Pract Res Clin Haematol 2005 18 : 389 406.
48. Rader M. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits. Oncology (Williston Park) 2006 20 (Suppl. 4 16 21.
49. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001 113 : 590 5.
50. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60D 6D.
51. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997 15 : 3368 77.
52. McHutchison JG, Afdahl N, Shiffman ML, et al. Efficacy and Safety of Eltrombopag, An Oral Platelet Growth Factor, in Subjects with HCV Associated Thrombocytopenia: Preliminary Results from a Phase II Multicenter, Randomised, Placebo Controlled, Double-Blind, Dose-Ranging Study [Abstract]. Presented at Digestive Disease Week, 20-25 May 2006, Los Angeles, CA (A338).
53. Bhatia M, Davenport V, Cairo MS. The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. Leuk Lymphoma 2007 48 : 9 15.
54. Kuter DJ. New thrombopoietic growth factors. Blood 2007 109 : 4607 16.
55. Lawitz EJ, Hepburn MJ, Casey TJ. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004 99 : 2359 64.
56. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest 2001 119 : 1489 97.
57. Kim WR. The burden of hepatitis C in the United States. Hepatology 2002 36 (Suppl. 1 S30 4.
58. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006 24 : 661 72.
59. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001 6 (Suppl. 5 15 23.